+

WO1999041402A3 - Ciblage de vecteurs de vaccins genetiques - Google Patents

Ciblage de vecteurs de vaccins genetiques Download PDF

Info

Publication number
WO1999041402A3
WO1999041402A3 PCT/US1999/003023 US9903023W WO9941402A3 WO 1999041402 A3 WO1999041402 A3 WO 1999041402A3 US 9903023 W US9903023 W US 9903023W WO 9941402 A3 WO9941402 A3 WO 9941402A3
Authority
WO
WIPO (PCT)
Prior art keywords
targeting
genetic vaccine
vaccine vectors
target cell
tissue type
Prior art date
Application number
PCT/US1999/003023
Other languages
English (en)
Other versions
WO1999041402A2 (fr
Inventor
Juha Punnonen
Willem P C Stemmer
Russell Howard
Phillip A Patten
Original Assignee
Maxygen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen Inc filed Critical Maxygen Inc
Priority to MXPA00007893A priority Critical patent/MXPA00007893A/es
Priority to CA002320431A priority patent/CA2320431A1/fr
Priority to AU26742/99A priority patent/AU2674299A/en
Priority to EP99906949A priority patent/EP1053343A2/fr
Priority to JP2000531583A priority patent/JP2002503478A/ja
Publication of WO1999041402A2 publication Critical patent/WO1999041402A2/fr
Publication of WO1999041402A3 publication Critical patent/WO1999041402A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C12N15/1027—Mutagenizing nucleic acids by DNA shuffling, e.g. RSR, STEP, RPR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des procédés permettant d'obtenir des réactifs destinés à augmenter la spécificité des vaccins génétiques, pour une cellule cible ou un type de tissu désirés. L'invention concerne également des véhicules d'administration utilisés pour améliorer la spécificité du vaccin génétique pour une cellule cible ou un type de tissu.
PCT/US1999/003023 1998-02-11 1999-02-10 Ciblage de vecteurs de vaccins genetiques WO1999041402A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
MXPA00007893A MXPA00007893A (es) 1998-02-11 1999-02-10 Direccion de vectores de vacunas geneticas.
CA002320431A CA2320431A1 (fr) 1998-02-11 1999-02-10 Ciblage de vecteurs de vaccins genetiques
AU26742/99A AU2674299A (en) 1998-02-11 1999-02-10 Targeting of genetic vaccine vectors
EP99906949A EP1053343A2 (fr) 1998-02-11 1999-02-10 Ciblage de vecteurs de vaccins genetiques
JP2000531583A JP2002503478A (ja) 1998-02-11 1999-02-10 遺伝子ワクチンベクターの標的化

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2176998A 1998-02-11 1998-02-11
US7429498P 1998-02-11 1998-02-11
US60/074,294 1998-02-11
US09/021,769 1998-02-11

Publications (2)

Publication Number Publication Date
WO1999041402A2 WO1999041402A2 (fr) 1999-08-19
WO1999041402A3 true WO1999041402A3 (fr) 1999-11-11

Family

ID=26695070

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/US1999/003022 WO1999041369A2 (fr) 1998-02-11 1999-02-10 Vecteurs de vaccins mis au point par genie genetique
PCT/US1999/003023 WO1999041402A2 (fr) 1998-02-11 1999-02-10 Ciblage de vecteurs de vaccins genetiques
PCT/US1999/003020 WO1999041368A2 (fr) 1998-02-11 1999-02-10 Optimisation des proprietes immunomodulatrices des vaccins genetiques

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US1999/003022 WO1999041369A2 (fr) 1998-02-11 1999-02-10 Vecteurs de vaccins mis au point par genie genetique

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US1999/003020 WO1999041368A2 (fr) 1998-02-11 1999-02-10 Optimisation des proprietes immunomodulatrices des vaccins genetiques

Country Status (6)

Country Link
EP (3) EP1056842A2 (fr)
JP (3) JP2002503461A (fr)
AU (3) AU2674299A (fr)
CA (3) CA2320431A1 (fr)
MX (3) MXPA00007889A (fr)
WO (3) WO1999041369A2 (fr)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6917882B2 (en) 1999-01-19 2005-07-12 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US6958213B2 (en) 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
US6961664B2 (en) 1999-01-19 2005-11-01 Maxygen Methods of populating data structures for use in evolutionary simulations
US7024312B1 (en) 1999-01-19 2006-04-04 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US7058515B1 (en) 1999-01-19 2006-06-06 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US7074590B2 (en) 2000-06-23 2006-07-11 Maxygen, Inc. Chimeric promoters
US7115712B1 (en) 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
US7148054B2 (en) 1997-01-17 2006-12-12 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
US7153655B2 (en) 1998-06-16 2006-12-26 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
US7262012B2 (en) 2002-05-17 2007-08-28 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function using varied exonuclease digestion in two polynucleotide populations
US7390619B1 (en) 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
US7430477B2 (en) 1999-10-12 2008-09-30 Maxygen, Inc. Methods of populating data structures for use in evolutionary simulations
US7462469B2 (en) 2000-01-11 2008-12-09 Maxygen, Inc. Integrated system for diversity generation and screening
US9512382B2 (en) 2009-10-16 2016-12-06 Bunge Global Innovation, Llc Oil degumming methods

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
AU7690898A (en) 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
US6399383B1 (en) 1997-10-28 2002-06-04 Maxygen, Inc. Human papilloma virus vectors
AU1449499A (en) 1997-10-31 1999-05-24 Maxygen, Incorporated Modification of virus tropism and host range by viral genome shuffling
US6908757B1 (en) 1998-03-26 2005-06-21 The Procter & Gamble Company Serine protease variants having amino acid deletions and substitutions
KR20010052894A (ko) 1998-06-17 2001-06-25 맥시겐, 인크. 목적하는 특성을 보유한 폴리뉴클레오티드를 생성하는 방법
CA2332615A1 (fr) 1998-08-12 2000-02-24 Maxygen Inc. Rearrangement d'adn de genes de monoxygenase en vue de la production de produits chimiques industriels
EP1119616A2 (fr) 1998-10-07 2001-08-01 Maxygen, Inc. Rearrangement d'adn pour produire des acides nucleiques de detoxication contre les mycotoxines
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
EP1129184A1 (fr) 1998-11-10 2001-09-05 Maxygen, Inc. Adp-glucose pyrophosphorylase modifiee pour l'amelioration et l'optimisation de phenotypes vegetaux
ATE439437T1 (de) 1999-01-05 2009-08-15 Univ Boston Verbessertes klonierungsverfahren
US6436675B1 (en) 1999-09-28 2002-08-20 Maxygen, Inc. Use of codon-varied oligonucleotide synthesis for synthetic shuffling
US6376246B1 (en) 1999-02-05 2002-04-23 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
EP1073710A4 (fr) * 1999-02-04 2007-12-19 Verenium Corp Elaboration non stochastique de vaccins genetiques et d'enzymes
US7384387B1 (en) 1999-02-11 2008-06-10 Maxygen, Inc. High throughput mass spectrometry
US6531316B1 (en) 1999-03-05 2003-03-11 Maxyag, Inc. Encryption of traits using split gene sequences and engineered genetic elements
US6946128B1 (en) 1999-07-22 2005-09-20 The Procter & Gamble Company Protease conjugates having sterically protected epitope regions
JP2003505070A (ja) 1999-07-22 2003-02-12 ザ、プロクター、エンド、ギャンブル、カンパニー 定められたエピトープ領域においてアミノ酸置換を有するサブチリシンプロテアーゼ変異体
JP2003516116A (ja) 1999-07-22 2003-05-13 ザ、プロクター、エンド、ギャンブル、カンパニー 立体的に保護されたクリップ部位を有するプロテアーゼ抱合体
BR0012693A (pt) 1999-07-22 2002-04-09 Procter & Gamble Variante, de protease tipo subtilisina; composição de limpeza; e composição de cuidado pessoal
US6686515B1 (en) 1999-11-23 2004-02-03 Maxygen, Inc. Homologous recombination in plants
US6998263B2 (en) 2000-02-09 2006-02-14 Genvec, Inc. Methods of preparing and using a viral vector library
AU5995701A (en) * 2000-05-26 2001-12-03 Univ Australian Synthetic peptides and uses therefore
AUPQ776100A0 (en) 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
US7094875B2 (en) 2000-06-23 2006-08-22 Maxygen, Inc. Co-stimulatory polypeptides
US20030165538A1 (en) * 2000-06-26 2003-09-04 Maxygen Incorporated Methods and compositions for developing spore display systems for medicinal and industrial applications
US6858422B2 (en) 2000-07-13 2005-02-22 Codexis, Inc. Lipase genes
DE10060959A1 (de) * 2000-12-06 2002-06-20 Aventis Res & Tech Gmbh & Co Verfahren zur Isolierung und Identifizierung von Effektoren
CA2436214C (fr) * 2001-02-02 2012-12-04 Large Scale Biology Corporation Procede destine a ameliorer la complementarite d'un heteroduplex
AU2002309989A1 (en) 2001-05-18 2002-12-03 Rigel Pharmaceuticals, Incorporated Directed evolution of protein in mammalian cells
AU2002326437A1 (en) * 2001-07-19 2003-03-03 Icogen Corporation Methods for the identification of peptidyl compounds interacting with extracellular target molecules
IL162077A0 (en) * 2001-11-21 2005-11-20 Univ Leland Stanford Junior Polynucleotide therapy the board of trustees of the leland stanford junior university
AU2003267943C1 (en) 2002-02-26 2009-05-21 Altravax, Inc. Novel flavivirus antigens
DK2390803T3 (da) 2002-03-01 2014-01-27 Codexis Mayflower Holdings Llc Fremgangsmåder, systemer og software til identificering af funktionelle biomolekyler
US7620500B2 (en) 2002-03-09 2009-11-17 Maxygen, Inc. Optimization of crossover points for directed evolution
US7226771B2 (en) 2002-04-19 2007-06-05 Diversa Corporation Phospholipases, nucleic acids encoding them and methods for making and using them
WO2003089620A2 (fr) 2002-04-19 2003-10-30 Diversa Corporation Phospholipases, acides nucleiques codant pour ces phosphalipases et methodes de fabrication et d'utilisation
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
EP2275536A1 (fr) 2002-08-06 2011-01-19 Verdia, Inc. Variants de l'amine oxydase AP1
WO2004058278A1 (fr) 2002-12-16 2004-07-15 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Virus de la vaccine recombinants exprimant il-15 et methodes d'utilisation desdits virus
CN104388449A (zh) 2003-03-06 2015-03-04 维莱尼姆公司 淀粉酶、编码它们的核酸及其制备和应用方法
DK2853593T3 (en) 2003-03-07 2018-01-08 Dsm Ip Assets Bv Hydrolases, nucleic acids encoding them, and processes for their preparation and use
DK1613733T3 (en) 2003-04-04 2015-08-31 Basf Enzymes Llc PEKTATLYASER, nucleic acids encoding them, and methods for making and using the
EP1620557A2 (fr) 2003-04-29 2006-02-01 Pioneer Hi-Bred International, Inc. Genes de la glyphosate-n-acetyltransferase (gat)
NZ570709A (en) * 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
CN103484485B (zh) 2003-07-02 2017-08-15 Bp法人北美有限公司 葡聚糖酶，编码它们的核酸以及制备和使用它们的方法
CA2891101A1 (fr) 2003-08-11 2005-03-10 Basf Enzymes Llc Laccases, acides nucleiques codant pour ces enzymes et procedes permettant de les produire et de les utiliser
CA2734716A1 (fr) 2004-06-09 2005-12-29 Pioneer Hi-Bred International, Inc. Peptides de transit vers des plastes
CN101432292B (zh) 2004-06-16 2013-03-13 维莱尼姆公司 对叶绿素进行酶促脱色的组合物和方法
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
EP2886658A1 (fr) 2005-03-10 2015-06-24 BASF Enzymes LLC Enzymes de lyase, acides nucléiques les codant et leurs procédés de fabrication et d'utilisation
NZ561247A (en) 2005-03-15 2010-06-25 Verenium Corp Beta-glucosidases, nucleic acids encoding them and methods for making and using them
US8715988B2 (en) 2005-03-28 2014-05-06 California Institute Of Technology Alkane oxidation by modified hydroxylases
EP2216403A3 (fr) 2006-02-02 2010-11-24 Verenium Corporation Estérases et acides nucléiques associés et procédés
CN103555741A (zh) 2006-02-10 2014-02-05 维莱尼姆公司 纤维素分解酶、其编码核酸及制备和使用它们的方法
USRE45660E1 (en) 2006-02-14 2015-09-01 Bp Corporation North America Inc. Xylanases, nucleic acids encoding them and methods for making and using them
US8546118B2 (en) 2006-03-07 2013-10-01 Verenium Corporation Aldolases, nucleic acids encoding them and methods for making and using them
CA2643416C (fr) 2006-03-07 2016-07-26 Cargill, Incorporated Aldolases, acides nucleiques les codant et procedes de fabrication et d'utilisation de celles-ci
CN106222185B (zh) 2006-08-04 2021-12-03 维莱尼姆公司 葡聚糖酶、编码它们的核酸及制备和使用它们的方法
AR062947A1 (es) 2006-09-21 2008-12-17 Verenium Corp Fosfolipasas acidos nucleicos que las codifican y metodos para prepararlas y usarlas
EP2617814B1 (fr) 2006-09-21 2015-11-18 BASF Enzymes LLC Phytases, acides nucléiques encodant celles-ci et méthodes pour leur fabrication et leur utilisation
HUE033455T2 (en) 2006-12-21 2017-12-28 Basf Enzymes Llc Amylases and glucoamylases, nucleic acids encoding them, and methods for their preparation and use
AU2008210495B2 (en) 2007-01-30 2014-02-27 Bp Corporation North America, Inc. Enzymes for the treatment of lignocellulosics, nucleic acids encoding them and methods for making and using them
CN103757036B (zh) 2007-10-03 2019-10-01 维莱尼姆公司 木聚糖酶、编码它们的核酸以及其制备和应用方法
DK2222697T3 (da) 2007-11-01 2013-03-11 Perseid Therapeutics Llc Immunsuppressive polypeptider og nukleinsyrer
EP2706122A3 (fr) 2008-01-03 2014-06-18 Verenium Corporation Isomérases, acides nucléiques les codant et leurs procédés de fabrication et d'utilisation
WO2009088949A1 (fr) 2008-01-03 2009-07-16 Verenium Corporation Transférases et oxydoréductases, acides nucléiques codant pour celles-ci, et leurs procédés de fabrication et d'utilisation
US8101819B2 (en) 2008-05-23 2012-01-24 E. I. Dupont De Nemours And Company DGAT genes for increased seed storage lipid production and altered fatty acid profiles in oilseed plants
US8198062B2 (en) 2008-08-29 2012-06-12 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
ES2709481T3 (es) 2008-09-26 2019-04-16 Tocagen Inc Vectores recombinantes
DK2432797T3 (en) 2009-05-21 2017-01-16 Basf Enzymes Llc PHYTASES, NUCLEIC ACIDS, CODING THESE, AND METHODS OF PRODUCING AND USING THEREOF
WO2011022597A1 (fr) 2009-08-20 2011-02-24 Pioneer Hi-Bred International, Inc. Expression fonctionnelle d'un transporteur de nitrate de levure brassé (ynti) chez le maïs pour améliorer l'absorption du nitrate dans un environnement pauvre en nitrate
UA109884C2 (uk) 2009-10-16 2015-10-26 Поліпептид, що має активність ферменту фосфатидилінозитол-специфічної фосфоліпази с, нуклеїнова кислота, що його кодує, та спосіб його виробництва і застосування
US20110191903A1 (en) 2009-12-31 2011-08-04 Pioneer Hi-Bred International, Inc. Engineering plant resistance to diseases caused by pathogens
CA2805937A1 (fr) 2010-08-13 2012-02-16 Pioneer Hi-Bred International, Inc. Promoteurs chimeres et leurs methodes d'utilisation
WO2013166113A1 (fr) 2012-05-04 2013-11-07 E. I. Du Pont De Nemours And Company Compositions et procédés comprenant des séquences ayant une activité de méganucléase
AU2014236154A1 (en) 2013-03-14 2015-09-17 Pioneer Hi-Bred International, Inc. Compositions having dicamba decarboxylase activity and methods of use
US20160040149A1 (en) 2013-03-14 2016-02-11 Pioneer Hi-Bred International Inc. Compositions Having Dicamba Decarboxylase Activity and Methods of Use
MX360160B (es) 2013-03-15 2018-10-24 Pioneer Hi Bred Int Polipeptidos phi-4 y metodos para su uso.
CN106232820A (zh) 2013-08-16 2016-12-14 先锋国际良种公司 杀昆虫蛋白及其使用方法
WO2015038734A2 (fr) 2013-09-13 2015-03-19 Pioneer Hi-Bred International, Inc. Protéines insecticides et leurs procédés d'utilisation
BR112016018287A2 (pt) 2014-02-07 2017-10-10 Du Pont proteínas inseticidas e métodos para uso das mesmas
WO2015120270A1 (fr) 2014-02-07 2015-08-13 Pioneer Hi Bred International, Inc. Protéines insecticides et leurs procédés d'utilisation
WO2016038895A1 (fr) * 2014-09-11 2016-03-17 Vlp Therapeutics, Llc Particule pseudo-virale du flavivirus
MX381370B (es) 2014-10-16 2025-03-12 Corteva Agriscience Llc Proteinas insecticidas y metodos de uso.
US10231460B2 (en) 2015-01-15 2019-03-19 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
CN107529763B (zh) 2015-03-11 2021-08-20 先锋国际良种公司 Pip-72的杀昆虫组合及使用方法
RU2017144238A (ru) 2015-05-19 2019-06-19 Пайонир Хай-Бред Интернэшнл, Инк. Инсектицидные белки и способы их применения
BR122023016256B8 (pt) 2015-08-06 2024-04-30 Du Pont Polipeptídeo inseticida recombinante, polinucleotídeo recombinante, construto de dna, método de obtenção de uma planta transgênica ou célula de planta transgênica, composição, proteína de fusão, método para controlar uma praga, método para inibir crescimento ou para exterminar uma população de pragas e uso do polipeptídeo
US20180325119A1 (en) 2015-12-18 2018-11-15 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
EA201892293A1 (ru) 2016-05-04 2019-04-30 Пайонир Хай-Бред Интернэшнл, Инк. Инсектицидные белки и способы их применения
US11001858B2 (en) * 2016-06-20 2021-05-11 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
EP3478052B1 (fr) 2016-07-01 2021-08-25 Pioneer Hi-Bred International, Inc. Protéines insecticides issues de plantes et procédés pour leur utilisation
EP4050021A1 (fr) 2016-11-01 2022-08-31 Pioneer Hi-Bred International, Inc. Protéines insecticides et leurs procédés d'utilisation
CN110088123B (zh) 2016-12-14 2023-10-20 先锋国际良种公司 杀昆虫蛋白及其使用方法
MX2019007491A (es) 2016-12-22 2019-09-06 Pioneer Hi Bred Int Proteinas insecticidas y metodos para su uso.
CA3052794A1 (fr) 2017-02-08 2018-08-16 Pioneer Hi-Bred International, Inc. Associations insecticides de proteines insecticides d'origine vegetale et leurs procedes d'utilisation
EP3622076B1 (fr) 2017-05-11 2025-04-16 Pioneer Hi-Bred International, Inc. Protéines insecticides et leurs procédés d'utilisation
US11820791B2 (en) 2018-03-14 2023-11-21 Pioneer Hi-Bred International, Inc. Insecticidal proteins from plants and methods for their use
CN112020302B9 (zh) 2018-03-14 2023-05-09 先锋国际良种公司 来自植物的杀昆虫蛋白及其使用方法
EP3947442A2 (fr) 2019-03-28 2022-02-09 Danisco US Inc. Anticorps modifiés
KR20220126740A (ko) 2020-01-10 2022-09-16 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 올리베톨산 및 올리베톨산 유사체 생산을 위한 생합성 플랫폼
US12168774B2 (en) 2020-07-14 2024-12-17 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0125228A1 (fr) * 1983-04-29 1984-11-14 The President And Fellows Of Harvard College Plasmides et souches modifiées de Vibrio cholerae, leur préparation et vaccins en derivés
WO1991007979A1 (fr) * 1989-11-29 1991-06-13 Center For Innovative Technology Proteines chimeriques
WO1994023738A1 (fr) * 1993-04-19 1994-10-27 Medisorb Technologies International L.P. Encapsulation d'acides nucleiques avec des conjugues qui facilitent et ciblent l'absorption cellulaire et l'expression genique
WO1994025608A1 (fr) * 1993-04-27 1994-11-10 Baylor College Of Medicine Proteines de fixations d'adn naturel ou recombine utilisees comme vecteurs dans le transfert de genes ou la therapie genique
WO1994026787A1 (fr) * 1993-05-07 1994-11-24 The Board Of Trustees Of The Leland Stanford Junior University Procede pour generer des bibliotheques d'anticorps de phages specifiques de types cellulaires
WO1995016027A1 (fr) * 1993-12-06 1995-06-15 Bioinvent International Ab Procede de selection de bacteriophages specifiques
WO1996013250A1 (fr) * 1994-10-27 1996-05-09 Amgem Inc. Compositions pour une assimilabilite accrue d'agents therapeutiques administres par voie orale
WO1996023882A1 (fr) * 1995-01-31 1996-08-08 The Rockefeller University IDENTIFICATION DE LA PROTEINE MEMBRANAIRE, INTEGRALE DEC (CELLULES DENDRITIQUES ET EPITHELIALES, 205 kDa), UN RECEPTEUR A DOMAINES LECTINIQUES DE TYPE C, DES ACIDES NUCLEIQUES CODANT DEC, AINSI QUE SES APPLICATIONS
WO1997011605A1 (fr) * 1995-09-28 1997-04-03 University Of Pittsburgh Of The Commonwealth System Of Higher Education Stimulation de reponses immunes cellulaires par une imunisation genique ciblee utilisant un agent particulaire
WO1997020078A1 (fr) * 1995-11-30 1997-06-05 Maxygen, Inc. Procede d'elaboration de polynucleotides presentant des caracteristiques desirees par selection iterative et recombinaison
WO1997035957A1 (fr) * 1996-03-25 1997-10-02 Maxygen, Inc. Absorption d'adn cellulaire par recombinaison recursive de sequences

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU712714B2 (en) * 1994-10-03 1999-11-11 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule B7 gene in a recombinant virus expressing system
EP0863913A4 (fr) * 1995-08-21 2001-04-11 Univ Duke Procede pour accroitre la densite d'un antigene sur une cellule presentant un antigene
US6489145B1 (en) * 1996-07-09 2002-12-03 Diversa Corporation Method of DNA shuffling
WO1997032987A1 (fr) * 1996-03-08 1997-09-12 University Of Toronto Procede et compositions nucleiques immunogenes codant pour des antigenes, et molecules co-stimulant l'immunisation

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0125228A1 (fr) * 1983-04-29 1984-11-14 The President And Fellows Of Harvard College Plasmides et souches modifiées de Vibrio cholerae, leur préparation et vaccins en derivés
WO1991007979A1 (fr) * 1989-11-29 1991-06-13 Center For Innovative Technology Proteines chimeriques
WO1994023738A1 (fr) * 1993-04-19 1994-10-27 Medisorb Technologies International L.P. Encapsulation d'acides nucleiques avec des conjugues qui facilitent et ciblent l'absorption cellulaire et l'expression genique
WO1994025608A1 (fr) * 1993-04-27 1994-11-10 Baylor College Of Medicine Proteines de fixations d'adn naturel ou recombine utilisees comme vecteurs dans le transfert de genes ou la therapie genique
WO1994026787A1 (fr) * 1993-05-07 1994-11-24 The Board Of Trustees Of The Leland Stanford Junior University Procede pour generer des bibliotheques d'anticorps de phages specifiques de types cellulaires
WO1995016027A1 (fr) * 1993-12-06 1995-06-15 Bioinvent International Ab Procede de selection de bacteriophages specifiques
WO1996013250A1 (fr) * 1994-10-27 1996-05-09 Amgem Inc. Compositions pour une assimilabilite accrue d'agents therapeutiques administres par voie orale
WO1996023882A1 (fr) * 1995-01-31 1996-08-08 The Rockefeller University IDENTIFICATION DE LA PROTEINE MEMBRANAIRE, INTEGRALE DEC (CELLULES DENDRITIQUES ET EPITHELIALES, 205 kDa), UN RECEPTEUR A DOMAINES LECTINIQUES DE TYPE C, DES ACIDES NUCLEIQUES CODANT DEC, AINSI QUE SES APPLICATIONS
WO1997011605A1 (fr) * 1995-09-28 1997-04-03 University Of Pittsburgh Of The Commonwealth System Of Higher Education Stimulation de reponses immunes cellulaires par une imunisation genique ciblee utilisant un agent particulaire
WO1997020078A1 (fr) * 1995-11-30 1997-06-05 Maxygen, Inc. Procede d'elaboration de polynucleotides presentant des caracteristiques desirees par selection iterative et recombinaison
WO1997035957A1 (fr) * 1996-03-25 1997-10-02 Maxygen, Inc. Absorption d'adn cellulaire par recombinaison recursive de sequences

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PATTEN P A ET AL: "APPLICATIONS OF DNA SHUFFLING TO PHARMACEUTICALS AND VACCINES", CURRENT OPINION IN BIOTECHNOLOGY, vol. 8, 1997, pages 724 - 733, XP002916609 *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7148054B2 (en) 1997-01-17 2006-12-12 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
US7629170B2 (en) 1997-01-17 2009-12-08 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
US7390619B1 (en) 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
US7153655B2 (en) 1998-06-16 2006-12-26 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
US7058515B1 (en) 1999-01-19 2006-06-06 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US6961664B2 (en) 1999-01-19 2005-11-01 Maxygen Methods of populating data structures for use in evolutionary simulations
US7620502B2 (en) 1999-01-19 2009-11-17 Maxygen, Inc. Methods for identifying sets of oligonucleotides for use in an in vitro recombination procedure
US6917882B2 (en) 1999-01-19 2005-07-12 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US7024312B1 (en) 1999-01-19 2006-04-04 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US7421347B2 (en) 1999-01-19 2008-09-02 Maxygen, Inc. Identifying oligonucleotides for in vitro recombination
US7430477B2 (en) 1999-10-12 2008-09-30 Maxygen, Inc. Methods of populating data structures for use in evolutionary simulations
US7115712B1 (en) 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
US7462469B2 (en) 2000-01-11 2008-12-09 Maxygen, Inc. Integrated system for diversity generation and screening
US7074590B2 (en) 2000-06-23 2006-07-11 Maxygen, Inc. Chimeric promoters
US7282334B2 (en) 2000-12-12 2007-10-16 Alligator Bioscience, Ab Method for in vitro molecular evolution of protein function
US7563578B2 (en) 2000-12-12 2009-07-21 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
US6958213B2 (en) 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
US7262012B2 (en) 2002-05-17 2007-08-28 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function using varied exonuclease digestion in two polynucleotide populations
US9512382B2 (en) 2009-10-16 2016-12-06 Bunge Global Innovation, Llc Oil degumming methods

Also Published As

Publication number Publication date
EP1053312A2 (fr) 2000-11-22
WO1999041368A3 (fr) 1999-12-16
CA2320431A1 (fr) 1999-08-19
WO1999041369A3 (fr) 1999-09-23
AU2674299A (en) 1999-08-30
EP1053343A2 (fr) 2000-11-22
CA2320626A1 (fr) 1999-08-19
MXPA00007891A (es) 2002-09-18
JP2002503478A (ja) 2002-02-05
WO1999041402A2 (fr) 1999-08-19
AU3291099A (en) 1999-08-30
JP2002503461A (ja) 2002-02-05
EP1056842A2 (fr) 2000-12-06
CA2320960A1 (fr) 1999-08-19
AU2674199A (en) 1999-08-30
JP2002507392A (ja) 2002-03-12
WO1999041369A2 (fr) 1999-08-19
MXPA00007889A (es) 2002-09-18
WO1999041368A2 (fr) 1999-08-19
MXPA00007893A (es) 2002-10-23

Similar Documents

Publication Publication Date Title
WO1999041402A3 (fr) Ciblage de vecteurs de vaccins genetiques
WO2002087510A3 (fr) Ciblage intracellulaire de proteines therapeutiques
WO2003020949A3 (fr) Produits de recombinaison cibles d'acides nucleiques et utilisations en rapport avec lesdits produits
WO1999038972A8 (fr) Genes humains et produits ii d'expression genique
EP2216407A3 (fr) Compositions Therapeutiques
GB2338484B (en) Medicaments comprising a nucleic acid encoding a cell targeting moiety and a prodrug activating enzyme
WO1997006662A3 (fr) Oligonucleotides chimeres et hybrides inverses
WO1999058675A3 (fr) Genes humains et produits d'expression genique v
WO1999047669A3 (fr) Sequences d'acide nucleique humain tirees de tissus de tumeurs du sein
WO2002014500A3 (fr) Genes humains et produits d'expression genique
WO2001066753A3 (fr) Nouveaux genes humains et leurs produits d'expression
WO2000066739A3 (fr) Antigenes de chlamydia, fragments d'adn correspondants et utilisation de ceux-ci
WO2006028429A3 (fr) Peptide pour cibler l'antigene prostatique membranaire specifique
WO1998046788A3 (fr) Nouvelles amorces et procedes de detection des cellules tumorales disseminees
IL135687A0 (en) A novel human checkpoint kinase, hcds1, compositions and methods
AU2001277653A1 (en) Diagnosis of known genetic parameters within the MHC
WO2004010925A3 (fr) Genes de mammifere impliques dans la suppression des infections virales et des tumeurs
EP1298208A3 (fr) Ribozymes contre une séquence de Tat de HIV
WO1999046374A3 (fr) Sequences d'acide nucleique humaines issues de tissus tumoraux prostatiques
AU5137498A (en) Iga nephropathy-associated gene
WO2002038612A3 (fr) Polypeptide
WO1998017814A3 (fr) Expression de genes, systemes d'apport et utilisations
WO1998058055A3 (fr) Acides nucleiques antisens diriges contre le virus de l'hepatite b
WO2000052164A3 (fr) Nouvelles molecules du canal potassique et leur utilisation
EP1103797A3 (fr) Balance

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2320431

Country of ref document: CA

Ref country code: CA

Ref document number: 2320431

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: JP

Ref document number: 2000 531583

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/007893

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 26742/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999906949

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999906949

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999906949

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载